Literature DB >> 433874

Group D streptococcal septicemia in the neonate.

K Bavikatte, R L Schreiner, J A Lemons, E L Gresham.   

Abstract

The clinical course of 11 patients with neonatal group D streptococcal septicemia is reviewed. Two of the infants died and hydrocephalus developed in one. Group D Streptococcus, both enterococci and nonenterococci, should be considered pathogenic in the neonate until proved otherwise. The antibiotics of choice for treating such infections in the newborn are ampicillin sodium and either kanamycin sulfate or gentamicin sulfate.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 433874     DOI: 10.1001/archpedi.1979.02130050037008

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  6 in total

1.  Neonatal septicemia.

Authors:  S P Khatua; A K Das; B D Chatterjee; S Khatua; B Ghose; A Saha
Journal:  Indian J Pediatr       Date:  1986 Jul-Aug       Impact factor: 1.967

2.  Species distribution of non-group D alpha-hemolytic streptococci in maternal genital and neonatal blood cultures.

Authors:  A A Haffar; P A Fuselier; C J Baker
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

Review 3.  Clinical manifestations of enterococcal infection.

Authors:  C M Lewis; M J Zervos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

Review 4.  Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and review.

Authors:  Patrick J Gavin; Richard B Thomson; Show-Jen Horng; Ram Yogev
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Clinical significance of enterococci in blood cultures from adult patients.

Authors:  L D Wells; A von Graevenitz
Journal:  Infection       Date:  1980       Impact factor: 3.553

6.  Streptococcus faecium outbreak in a neonatal intensive care unit.

Authors:  P E Coudron; C G Mayhall; R R Facklam; A C Spadora; V A Lamb; M R Lybrand; H P Dalton
Journal:  J Clin Microbiol       Date:  1984-12       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.